Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O43506
UPID:
ADA20_HUMAN
Alternative names:
-
Alternative UPACC:
O43506; Q6GTZ1; Q9UKJ9
Background:
Disintegrin and metalloproteinase domain-containing protein 20 plays a crucial role in reproductive biology, potentially influencing sperm maturation and fertilization processes. Its unique enzymatic and binding capabilities suggest a multifunctional role in cellular interactions and molecular signaling pathways.
Therapeutic significance:
Understanding the role of Disintegrin and metalloproteinase domain-containing protein 20 could open doors to potential therapeutic strategies.